JP2001354559A5 - - Google Patents

Download PDF

Info

Publication number
JP2001354559A5
JP2001354559A5 JP2001126061A JP2001126061A JP2001354559A5 JP 2001354559 A5 JP2001354559 A5 JP 2001354559A5 JP 2001126061 A JP2001126061 A JP 2001126061A JP 2001126061 A JP2001126061 A JP 2001126061A JP 2001354559 A5 JP2001354559 A5 JP 2001354559A5
Authority
JP
Japan
Prior art keywords
microparticles
internationally
abi
paclitaxel
simplicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001126061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001354559A (ja
Filing date
Publication date
Priority claimed from IT2000MI001107A external-priority patent/ITMI20001107A1/it
Application filed filed Critical
Publication of JP2001354559A publication Critical patent/JP2001354559A/ja
Publication of JP2001354559A5 publication Critical patent/JP2001354559A5/ja
Pending legal-status Critical Current

Links

JP2001126061A 2000-05-18 2001-04-24 固形腫瘍を処置するための薬物を調製するためのアルブミンで安定化されたパクリタキセルの使用およびそれにより得られる薬物 Pending JP2001354559A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000MI001107A ITMI20001107A1 (it) 2000-05-18 2000-05-18 Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
IT2000A001107 2000-05-18

Publications (2)

Publication Number Publication Date
JP2001354559A JP2001354559A (ja) 2001-12-25
JP2001354559A5 true JP2001354559A5 (https=) 2008-06-05

Family

ID=11445079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001126061A Pending JP2001354559A (ja) 2000-05-18 2001-04-24 固形腫瘍を処置するための薬物を調製するためのアルブミンで安定化されたパクリタキセルの使用およびそれにより得られる薬物

Country Status (22)

Country Link
US (1) US6652884B2 (https=)
EP (1) EP1155692B1 (https=)
JP (1) JP2001354559A (https=)
KR (2) KR20010105248A (https=)
CN (1) CN1198609C (https=)
AT (1) ATE267594T1 (https=)
AU (1) AU781517B2 (https=)
BR (1) BR0102040A (https=)
CA (1) CA2345482A1 (https=)
DE (1) DE60103453T2 (https=)
DK (1) DK1155692T3 (https=)
ES (1) ES2221874T3 (https=)
HU (1) HU229909B1 (https=)
IL (1) IL142674A0 (https=)
IT (1) ITMI20001107A1 (https=)
MX (1) MXPA01004980A (https=)
NO (1) NO330511B1 (https=)
NZ (1) NZ511201A (https=)
PT (1) PT1155692E (https=)
RU (1) RU2270003C2 (https=)
TR (1) TR200101353A3 (https=)
ZA (1) ZA200103755B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
CA2509365C (en) * 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
CN1925874B (zh) * 2002-12-09 2014-12-17 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
BRPI0617663A2 (pt) * 2005-10-21 2011-08-02 Panacea Biotec Ltd composições aperfeiçoadas para terapia de cáncer
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP2131821B1 (en) 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス, エルエルシー 再発性癌の処置のための方法および組成物
MX2010011165A (es) * 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
KR101090505B1 (ko) * 2008-12-30 2011-12-06 최은아 난담반을 포함하는 암 예방 및 치료용 조성물
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
JP6387389B2 (ja) * 2013-03-13 2018-09-05 アブラクシス バイオサイエンス, エルエルシー 小児充実性腫瘍の処置の方法
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
ES3009356T3 (en) 2015-06-29 2025-03-26 Abraxis Bioscience Llc Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
WO2018037595A1 (ja) 2016-08-26 2018-03-01 哲治 奥野 微小血管血流低減剤およびその利用
TWI660728B (zh) 2018-02-09 2019-06-01 National Chiao Tung University 胺基喹唑啉衍生物及其醫藥組合物與用途
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
BR112022007710A2 (pt) 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina
CN120919082A (zh) * 2025-10-16 2025-11-11 天津医科大学总医院 一种负载蛋白药物的GelMA微球、制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
NZ262679A (en) 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
PT1023050E (pt) * 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
CA2362338A1 (en) 1998-07-30 2000-02-10 Human Rt. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin

Similar Documents

Publication Publication Date Title
JP2001354559A5 (https=)
JP2004525194A5 (https=)
JP2003503454A5 (https=)
JP2002506648A5 (https=)
JP2005526147A5 (https=)
JP2005525451A5 (https=)
ATE296302T1 (de) 4-(1,3,4-thiadiazolyl-2-yl)-1,4-diazabizyklo- 3.2.2 nonanderivate, ihre herstellung und ihre therapeutische verwendung
EE200300236A (et) 1,2-difenüülasetidinoonid, nende kasutamine, ravim ja selle valmistamismeetod
AU2003291133A1 (en) Carbon nanotube particulates, compositions and use thereof
JP2003213455A5 (https=)
JP2005510235A5 (https=)
JP2004051896A5 (https=)
DE60203197D1 (de) 4-(oxadiazol-3-yl)-1,4-diazabizyklo[3.2.2]-nonanderivate, ihre herstellung und therapeutische verwendung
JP2005507358A5 (https=)
JP2005501968A5 (https=)
ATE331528T1 (de) Präparationen, die virus-ähnliche partikel als immunpotentiatoren enthalten und durch die schleimhaut verabreicht werden.
JP2004529205A5 (https=)
JP2002022755A5 (https=)
JP2000141643A5 (https=)
JP2006505391A5 (https=)
JP2005536763A5 (https=)
JP2004508063A5 (https=)
JP2006500360A5 (https=)
JP2003197278A5 (https=)
JP2006516021A5 (https=)